#aafth ,,congress  #b;d ,session  ,s4   
#afha  ,,an ,,act  ,to educate health   
care providers and the public on        
biosimilar biological products1 and for 
other purposes4  #a4 ,short title ,this 
,act may be cited as the ,advancing     
,education on ,biosimilars ,act of      
#bjbj4  #b4 ,education on biological    
products ,subpart #a of part ,f of title
 ,,iii of the ,public ,health ,service  
,act 7#db ,u4,s4,c4 #bfb et seq47 is    
amended by adding at the end the        
following3  #ceb;,a4 ,education on      
biological products  7a7 ,internet      
website  7#a7 ,in general ,the          
,secretary may maintain and operate an  
internet website to provide educational 
materials for health care providers1    
patients1 and caregivers1 regarding the 
meaning of the terms1 and the standards 
for review and licensing of1 biological 
products1 including biosimilar          
biological products and interchangeable 
biosimilar biological products4  7#b7   
,content ,educational materials provided

 under paragraph 7#a7 may include-- 7,a7
 explanations of key statutory and      
regulatory terms1 including biosimilar  
and interchangeable1 and clarification  
regarding the use of interchangeable    
biosimilar biological products2  7,b7   
information related to development      
programs for biological products1       
including biosimilar biological products
 and interchangeable biosimilar         
biological products and relevant        
clinical considerations for prescribers1
 which may include1 as appropriate and  
applicable1 information related to the  
comparability of such biological        
products2  7,c7 an explanation of the   
process for reporting adverse events for
 biological products1 including         
biosimilar biological products and      
interchangeable biosimilar biological   
products2 and  7,d7 an explanation of   
the relationship between biosimilar     
biological products and interchangeable 
biosimilar biological products licensed 
under section #cea7k7 and reference     

products 7as defined in section         
#cea7;i771 including the standards for  
review and licensing of each such type  
of biological product4  7#c7 ,format    
,the educational materials provided     
under paragraph 7#a7 may be-- 7,a7 in   
formats such as webinars1 continuing    
education modules1 videos1 fact sheets1 
infographics1 stakeholder toolkits1 or  
other formats as appropriate and        
applicable2 and  7,b7 tailored for the  
unique needs of health care providers1  
patients1 caregivers1 and other         
audiences1 as the ,secretary determines 
appropriate4  7#d7 ,other information   
,in addition to the information         
described in paragraph 7#b71 the        
,secretary shall continue to publish--  
7,a7 the action package of each         
biological product licensed under       
subsection 7a7 or 7k7 of section #cea2  
or  7,b7 the summary review of each     
biological product licensed under       
subsection 7a7 or 7k7 of section #cea4  
7#e7 ,confidential and trade secret     

information ,this subsection does not   
authorize the disclosure of any trade   
secret1 confidential commercial or      
financial information1 or other matter  
described in section #eeb7;b7 of title  
#e4  7b7 ,continuing education ,the     
,secretary shall advance education and  
awareness among health care providers   
regarding biological products1 including
 biosimilar biological products and     
interchangeable biosimilar biological   
products1 as appropriate1 including by  
developing or improving continuing      
education programs that advance the     
education of such providers on the      
prescribing of1 and relevant clinical   
considerations with respect to1         
biological products1 including          
biosimilar biological products and      
interchangeable biosimilar biological   
products4  4  ,passed the ,senate       
,december #ag1 #bjbj4,secretary